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Abstract: 
Background: In Burkina Faso, the polymerase chain reaction (PCR) assay is not routinely used in the biological 
qualification of blood donations and this constitutes a risk factor for the transmission of occult hepatitis B virus 
(HBV) infection during blood transfusion. The objective of this study is to determine the prevalence of occult B 
infection (OBI) among blood donors for the purposes of improved blood safety in Burkina Faso.               
Methodology: A descriptive cross-sectional study of 300 HBsAg negative blood donors was conducted in the 
city of Ouagadougou, Burkina Faso from April to October 2020. Anti-HBc antibody was determined using the 
BOSON® brand rapid tests. HBV DNA was detected in 75 selected donors by real-time PCR (rt PCR) using the 
7500 Fast Real Time PCR assay technique.                          
Results: Of the 300 HBsAg negative donors, 208 (69.3%) were males while 92 (30.7%) were females, with 
average age of 30.18 years. Anti-HBc antibody was detected in 39 cases (13%). Of the 75 donor samples 
tested by rt PCR, 3 (4%) were positive for HBV DNA (occult B infection); 2 of which were anti-HBc antibody 
positive (seropositive OBI) while 1 was anti-HBc antibody negative (seronegative OBI).    
Conclusion: Given the prevalence of OBI of 4% in this study and its consequences in blood recipients, it 
appears necessary that in addition to the classic serological markers of hepatitis B, to test for the presence of 
HBV DNA among blood donors in order to improve transfusion safety. 
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Résume:                            
Contexte: Au Burkina Faso, la polymérase chain réaction (PCR) n’est pas utilisée lors de la qualification 
biologique des dons et cela constitue un facteur de risque de transmission de l’Infection Occulte du virus B 
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(VHB) lors des transfusions sanguines. L’objectif de cette étude était de déterminer la prévalence de l’infection 
occulte B chez les donneurs de sang en vue d’une meilleure sécurité transfusionnelle.                 
Méthodologie: Une étude transversale prospective, réalisée d’avril à octobre 2020 dans la ville de 
Ouagadougou incluant 300 donneurs de sang AgHBs négatif. L’anticorps anti HBc a été déterminé par les tests 
rapides de marque BOSON®. L’ADN du VHB a été recherché chez 75 donneurs par PCR en temps réel (rt PCR) 
avec le 7500 Fast Real Time PCR.                            
Résultats: Parmi les 300 donneurs AgHBs négatifs, 208 (69,3%) étaient des hommes et 92 (30,7%) des 
femmes. L’âge moyen était de 30,18 ans. La recherche de l’Ac anti-HBc était positive dans 39 cas (13 %). 
Parmi les 75 échantillons passés à la rt PCR, 3 (4%) étaient positifs pour l’ADN du VHB. Sur les 3 cas d’ADN 
VHB positifs, 2 (66,67%) étaient positifs Ac anti HBc et 1 (33,33%) Ac anti HBc négatif.                 
Conclusion: Compte tenu de la prévalence de l’infection occulte B et ses conséquences chez les donneurs de 
sang et chez les receveurs, il devient nécessaire de rechercher, en plus des marqueurs sérologiques classiques 
de l’hépatite B, l’ADN VHB pour une meilleure sécurité transfusionnelle.   
Mots clés: Prévalence, Infection occulte de l’HBV, Donneurs de sang, Ouagadougou 
Introduction: 
       Hepatitis B virus (HBV) infection is a 
global public health challenge. According to 
the World Health Organization (WHO) in 2017 
there were nearly two billion people infected 
with HBV worldwide, including 360 million 
chronic carriers who are at risk of cirrhosis 
and hepatocellular carcinoma (HCC) (1). In 
Africa, chronic hepatitis is the second leading 
cause of death after tuberculosis, with more 
than 60 million people affected. Injection 
with non-sterile needles and sharps in health 
facilities, tattoos, scarifications, and to a 
lesser extent, blood transfusion are the 
various means of HBV transmission (2). In 
Burkina Faso, HBV infection is the major 
cause of hepatic cirrhosis and liver cancer 
(3). The country is among those with high 
endemicity, where the carriage of hepatitis B 
virus surface antigen (HBsAg) is high in the 
general population, with a prevalence varying 
from 9% to 15% in 2018 (4–7), and seropre- 
valence rate of 7.28% among blood donors in 
2017 (8).    
 In some people, there is persistence 
of HBV DNA in liver tissue and/or serum of 
individuals in whom the HBsAg is not detec- 
table in the blood, with or without the pre- 
sence of anti-HBc antibodies (9), which is 
referred to as occult B infection (OBI). This 
OBI occurs all over the world, but its fre- 
quency is linked to the prevalence of HBV 
infection in a specific geographical area. 
Occult HBV infection is transmissible through 
blood transfusion in the event of biological 
qualification of donations without the use of 
the polymerase chain reaction (PCR) assay, 
and through organ transplants. The preva- 
lence of occult HBV infection in Burkina Faso 
varies according to studies; Birama et al., 
(10) reported a prevalence rate of 7.3% in 
2018 in the population of Ouagadougou while 
Somda et al., (11) reported a seroprevalence 
rate of 32.8% among blood donors in 2016.
 The molecular mechanisms underlying 
the occurrence of OBI are diverse and play 
an important role in the development of 
hepatocellular cancer (12). Chronic carriage 
of hepatitis C virus (HCV) and human immu- 
nodeficiency virus (HIV) are associated with a 
high prevalence of OBI (13). In Burkina Faso, 
PCR assay is not used in the biological quali- 
fication of donations, and this constitutes a 
risk factor for transmission of OBI during 
blood transfusions. It is in order to determine 
the prevalence of OBI in blood donors in the 
city of Ouagadougou that this study was 
carried out, with the aim of ensuring better 
transfusion safety. 
Materials and method:  
Study setting and design  
 This was a descriptive cross-sectional 
study of blood donors declared suitable for 
blood donation and tested negative for HBsAg 
in Ouagadougou Regional Blood Transfusion 
Center of (CRTS/O) and the Pietro Annigoni 
Biomolecular Research Center (CERBA) from 
April to October 2020. The CRTS/O served as 
the site for collecting study samples as well 
as for testing HBsAg and anti-HBcAb in blood 
donors. The CERBA served as the site for the 
detection of HBV DNA by the real-time PCR 
assay. 
Sampling    
 All blood donors declared suitable for 
donation and tested negative for HBsAg were 
included in this study. A total of 300 ran- 
domly selected donors were divided into 6 
groups of 50, and one group consisted of 
samples collected and tested on the same 
day for anti-HBc antibody. In each group of 
50, 15 samples were randomly selected for 
the quantitative detection of HBV DNA, but 
included all anti-HBc antibody positive sam- 
ples, with a total of 75 HBsAg negative sam- 
ples (made of 39 anti-HBc positive and 36 
anti-HBc negative samples) as shown in the 
workflow diagram (Fig 1). 




Detection of HBsAg and anti-HBc antibody 
 The Cobas e 601 automaton was used 
for the detection of HBsAg at CRTS/O. This 
test is an immunoassay that uses electro- 
chemiluminescence for the qualitative detec- 
tion of hepatitis B surface antigen (HBsAg) in 
human serum and plasma. This automaton 
has a sensitivity of 99.9% and a specificity of 
100%. The method for the detection of anti-
HBc antibody was carried out using the rapid 
test 1H27C2 HBcAb IgG brand 'Boson'. The 
sensitivity of this test method is 97.2% and 
the specificity is 98.4%. 
Detection of HBV DNA by real time PCR 
 HBV DNA was extracted from 200µl of 
plasma using the PureLink® Genomic DNA 
Kits (Life Technologies, Van Alleen Way Carl- 
sbad, CA, USA) according to the manufac- 
turer's protocol. This is a column extraction 
method based on the principle of nucleic acid 
molecules retention on a silicate membrane 
(filter). Quantification of HBV DNA was per- 
formed on the 7500 Fast Real Time PCR mac- 
hine, in a reaction volume of 20μl containing 
10μl of oasigTM 2 x qPCR Master Mix, 1μl of 
HBV Primer/Probe mix, 4μl of nuclease-free 
water and 5μl of extracted DNA. The amount 
of viral load in the samples is related to the 
standard curve obtained by making a cascade 
dilution to 1/10 of the positive control provi- 
ded by the manufacturer (5 times). The 
concentration of control was 2x108 copies/ml. 
Statistical analysis   
 Data were analyzed using EPI INFO 
version 7.2 software. Chi-square was used to 
measure association between the variables, 
and the level of significance (p value) used 
was 0.05 
Ethical considerations   
 The study received approval from the 
CNTS Internal Scientific Review Committee 
(CIRS). The anonymity and confidentiality of 
serological results from blood donors were 
ensured.  
Results: 
 A total of 300 HBsAg negative blood 
donors, including 208 males (69.3%) and 92 
females (30.7%) participated in the study. 
The male to female ratio was 2.3 and the 
mean age was 30.18 years with a range of 
18-58 years. Majority of the donors were in 
the age groups 20-34 (68.0%) and 35-50 
(24.3%) years. Of the 300 donations, 201 
were collected at fixed sites and 99 at mobile 
sites. Table 1 shows the frequency distri- 
bution of the donors by age group and 
gender. The hepatitis B virus anti HBc anti- 
body was detected in 39 donors representing 
a prevalence of 13%. Table 2 shows the fre- 
quency distribution of anti-HBc antibody with 
respect to gender and age group of donors. 
 Of the 75 donors with undetectable 
HBsAg screened by real time PCR, HBV DNA 
was detected in 3, representing a rate of 4%. 
Of the 3 positive samples, 2 (2.7%) were anti 
HBc positive (seropositive OBI) and 1 (1.3%) 
was anti HBc antibody negative (seronegative 
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OBI). The viral load of samples with HBV DNA 
varied from 335 IU/ml - 26454 IU/ml. Table 
3 presents the prevalence of OBI with respect 
to gender and age groups. Table 4 presents 
the summary of the results of the three OBI 
cases with respect to the type of donor and 
the viral load. 
 
 
Table1: Gender and age group distribution of HBsAg negative blood donors at Ouagadougou Regional Blood 
Transfusion Center of (CRTS / O), Burkina Faso 
Socio-demographic characteristics Number (n) Percentage (%) 
 
Gender  
Male 208 69.3 
Female 92 30.7 
Age group (years 
<20 10 3.3 
20-34 204 68.0 
35-50 73 24.3 
> 50 13 4.3 




Table 2: Frequency of anti HBc antibodies with respect to gender and age group of HBsAg negative blood 












0.2705* Male 178 (85.6) 30 (14.4) 
Female 83 (90.2) 9 (9.8) 
Total 261 (87.0) 39 (13.0) 
Age group (years)  
9.8331 
 
0.0073** < 20 10 (100) 0 
20 – 34 184 (90.2) 20 (9.8) 
35 – 50 58 (79.5) 15 (20.5) 
> 50 9 (69.2) 4 (30.8) 
Total 261 (87.0) 39 (13.0) 
* = not statistically significant; ** = statistically significant; X2 = Chi square  
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Table 3: Prevalence of occult B infection (OBI)with respect to gender and age groups of donors 
Socio-demographic 
characteristics 
HBV DNA negative              
n (%) 
HBV DNA positive                                  n 
(%) 
Gender 
Male 56 (96.6) 2 (3.4) 
Female 16 (94.1) 1 (5.9) 
Total 72 (96.0) 3 (4.0) 
Age group (years) 
< 20 1 (100) 0 
20 – 34 38 (95.0) 2 (5.0) 
35 – 50 27 (96.4) 1 (3.6) 
> 50 6 (100) 0 
Total 72 (96.0) 3 (4.0) 
  
Table 4: Summary of the results of the three cases of occult hepatitis B infections 
Number sample Gender Age (years) Donor type Viral load (UI/mL) 
11190226100 Male  35  Occasional 8134 
11190228800 Male  38  Occasional 26454 
11190225140 Female  26  Occasional 337 
 
Discussion: 
 Among the 300 donors who made up 
the study population, males represented 
69.3% compared to 30.7% females, with a 
male to female ratio of 2.3, similar to that 
reported by Yooda et al (8) of 2.47 in 2017 
among blood donors in Ouagadougou. This 
can be explained by the much greater willing- 
ness of males to donate blood, unlike females 
where there are situations in which blood 
donation may be relatively contraindicated, 
such as pregnancy, menstruation, childbirth, 
and breastfeeding. The age group 20-34 year 
constituted the majority in the study, similar 
to the studies of Doumbia et al., (14) in 2015 
in Burkina Faso and Oluyinka et al., (15) in 
2015 among blood donors in Nigeria. This 
finding could probably be linked to the dyna- 
mism and ability of the young population to 
donate blood. It is all fairer to say that the 
best blood donors in Burkina Faso are pupils 
and students (8).   
 The prevalence of anti-HBc antibody 
of 13% in this study is lower than the rate of 
18.4% reported by Yooda et al., (8) in 2017 
and 44.0% by Somda et al., (11) in 2016 
among blood donors in Burkina Faso. How- 
ever, it is higher than the 7.8% rate reported 
among blood donors in Egypt by Antar et al., 
(16) in 2010. The difference in rates reported 
may be due to the variations in sample size 
and study population, type of methods used, 
countries of study and the levels of HBV 
endemicity. Carriage of the anti HBc antibody 
is associated with the age of the study popu- 
lation. The age group over 50 years were 
most positive (30.8%) for anti-HBC antibody 
in our study. Burkina Faso is one of the areas 
of high endemicity of the hepatitis B virus, 
and very often, the infection is contracted 
early in childhood and develops in a latent 
fashion. Chronic active HBV infection usually 
occurs late and may progress to cirrhosis or 
primary liver cancer.   
 In the present study, we recorded a 
prevalence of 4% for occult HBV infection, 
which may be linked to the endemicity of 
HBV in Burkina Faso. This rate is lower than 
7.3% reported in Ouagadougou by Birama et 
al., (10) in 2018 and 32.8% reported among 
blood donors in Burkina Faso by Somda et 
al., in 2016 (11). On the other hand, this 
prevalence rate is closely related to 4.72% 
reported among blood donors in Ouagadou- 
gou by Yooda et al., (8) in 2017 but higher 
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than 0.56% and 2.86% rates reported among 
blood donors respectively in Cameroon by 
Fopa et al., in 2019 (17) and in China by Ye 
et al., in 2017 (18). Although, several studies 
have shown that OBI depends on the ende- 
micity of HBV, it is not limited to only 
countries with high HBV endemicity (10).  
The quality of the sample tested (blood or 
liver tissue) as well as the risks of conta- 
mination can also affect the detection of OBI 
(19).     
 In our study, donors with HBV DNA 
had viral load greater than 200 IU/ml (337- 
26,454 IU/ml). In 2008, the expert meeting 
clarified the definition of OBI by establishing 
cut-off value for serum HBV DNA <200 IU/ml 
(20). In addition, it also clarified the confu- 
sion between overt HBV infection and “false” 
OBI. Thus, cases where viral loads are com- 
parable to stages of overt HBV infection are 
usually due to infection with escape mutants 
and should be labeled as "false" OBIs (20), 
because these cases are in fact overt chronic 
hepatitis B. This is attributed to escape muta- 
tions that could have altered the target epi- 
tope of the HBsAg test (21). We believe that 
disregarding these definitions may contribute 
to overestimation of the prevalence of OBI. 
  In the present study, the viral loads 
being greater than 200 IU/ml, is in favor of 
“false” OBIs. Of the 3 donors positive for HBV 
DNA, two were HBV anti-HBc antibody posi- 
tive while one was negative. The two donors 
with positive anti-HBc antibody are consi- 
dered as cases of occult B seropositive OBI 
while the one negative donor is considered a 
seronegative OBI, which is an indication of a 
recent HBV infection not detectable by the 
test method used. 
Conclusion: 
 Occult HBV infection remains a big 
concern in Burkina Faso, as demonstrated by 
our current study and several other studies. 
Given the prevalence of OBI of 4% in this 
study and the consequences in blood reci- 
pients, it appears necessary that in addition 
to the detection of classic serological markers 
of hepatitis B, the presence of HBV DNA 
among blood donors should be tested, in 
order to ensure better transfusion safety. 
References: 
1. WHO. Disponible sur: https://apps.who.int/iris/ 
 bitstream/handle/10665/232529/WER7928_255-263 
 [cité 16 Jul 2019]                                                      
2.  Hepatitis WHO Regional Office for Africa. 
 https://www.afro.who.int/health-topics/hepatitis  
 accessed:29Jul2019                                                                       
3.  Lingani, M., Akita, T., Ouoba, S., et al. High 
 prevalence of hepatitis B infections in Burkina 
 Faso (1996–2017): a systematic review with 
 meta-analysis of epidemiological studies. BMC 
 Public Health. 2019; 18. https://www. ncbi.nlm. 
 nih.gov/pmc/articles/PMC5921387/                      
4.  Simpore, J., Savadogo, A., Ilboudo, D., et al. 
 Toxoplasma gondii, HCV, and HBV sero- 
 prevalence and co-infection among HIV-positive 
 and -negative pregnant women in Burkina Faso. 
 J Med Virol.  2006 ;78 (6) :730‑733.                                                                        
5.  Pietra, V., Kiema, D., Sorgho, D., Puoti, M., and 
 Simpore, J. Prévalence des marqueurs du virus 
 de l’hépatite B et des anticorps contre le virus 
 de l’hépatite C parmi le personnel du District 
 Sanitaire de Nanoro, Burkina Faso. 2008; 31 
 (1): 1-15                                                         
6.  Tao, I., Compaoré, T. R., Diarra, B., et al. 
 Seroepidemiology of Hepatitis B and C Viruses in 
 the General Population of Burkina Faso. Hepat 
 Res Treat. 2014; 2014: 1‑5.                         
7.  Sanou, A. M., Benkirane, K., Tinto, B., et al. 
 Prevalence of Hepatitis B virus and Hepatitis D 
 virus Coinfection in  Western Burkina Faso and 
 molecular characterization of the detected virus 
 strains. Int J Infect Dis 2018; 70: 15‑19.                                                                        
8.  Yooda, A. P., Soubeiga, S. T., Nebie, K. Y., et al. 
 Impact of Multiplex PCR in Reducing the Risk of 
 Residual Transfusion-Transmitted Human 
 Immunodeficiency and Hepatitis B and C Viruses 
 in Burkina Faso. Mediterr J Hematol Infect Dis. 
 2018; 10 (1): 1-9                                              
9.  Healthcote, J. Abbas, Z., Alberti, A., et al. WGO 
 Guideline. Hépatite B. 2008: 31                                            
10.  Yonli, A. T. Problematique de l’hepatite virale B 
 au Burkina Faso: Prévalence, caractéristiques 
 moléculaires des hepatites B chroniques et role 
 des genes GSTM1 et GSTT1 dans la survenue du 
 carcinome Hépatocellulaire. 2019.                                                                                              
11.  Somda, K. S., Sermé, A. K., Coulibaly, A., et al. 
 Hepatitis B Surface Antigen Should Not Be the 
 Only Sought Marker to Distinguish Blood Donors 
 towards Hepatitis B Virus Infection in High 
 Prevalence Area. Open J Gastroenterol. 2016; 
 06: 362-372                                              
12.  Vivekanandan, P., Kannangai, R., Ray, S. C., 
 Thomas, D. L., and Torbenson, M. Compre- 
 hensive genetic and epigenetic analysis of occult 
 hepatitis B from liver tissue samples. Clin Infect 
 Dis. 2008; 46 (8): 1227‑1236.                                                                     
13.  Khattab, E., Chemin, I., Vuillermoz, I., et al. 
 Analysis of HCV co-infection with occult hepatitis 
 B virus in patients  undergoing IFN therapy. J 
 Clin Virol. 2005; 33 (2): 150‑157.                       
14.  Doumbia, B. Caractérisation de l’infection occulte au 
 virus Caractérisation de l’infection  occulte au virus de 
 l’hépatite  B dans la population de Ouagadougou, 
 Mémoire Pour l’obtention du Master II de Biologie 
 Moléculaire et de Génétique Moléculaire Appliquées de 
 l’Université Ouaga 1 Pr. Joseph KI ZERBO                                      
15.  Oluyinka, O. O., Tong, H. V., Bui Tien, S., et al. 
 Occult Hepatitis B Virus Infection in Nigerian Blood 
 Donors and Hepatitis B Virus Transmission Risks. PLoS 
 One. 2015; 10 (7):  1-13                                
16.  Antar, W., El-Shokry, M. H., Abd El Hamid, W. 
 A., and Helmy, M. F. Significance of detecting  anti-HBc 
 among Egyptian male blood donors negative for HBsAg. 
 Transfus Med. 2010; 20 (6): 409 ‑ 413.                                                           
17.  Fopa, D., Candotti, D., Tagny, C. T., et al. Occult 
 hepatitis B infection among blood donors from 
 Yaoundé, Cameroon. Blood Transfus Sangue.  2019; 17 
 (6): 403‑408.                                                       
18.  Ye, X., Li, T., Xu, X., et al. Characterisation and 
 follow-up study of occult hepatitis B virus infection 
 in anti-HBc-positive qualified blood donors in southern 
 China. Blood Transfus  Sangue.2017;15(1):6‑12.                                    
19.  Zhu, H. L., Li, X., Li, J., and Zhang, Z. H. Genetic 
 variation of occult hepatitis B virus infection. World J 
 Gastroenterol. 2016; 22 (13): 3531‑3546.                            
20.  Raimondo, G., Allain, J. P., Brunetto, M. R., et 
 al. Statements from the Taormina expert meeting 
 on occult hepatitis B virus infection. J Hepatol. 2008; 
 49 (4): 652 ‑ 657.                                                      
21.  Bremer, C. M., Saniewski, M., Wend, U. C., et al. 
 Transient occult hepatitis B virus infection in a 
 blood donor with high viremia. Transfusion (Paris). 
 2009; 49 (8): 1621‑1629.  
